DUBLIN, Sept. 17, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Breast Cancer Market 2014-2018" report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
Breast cancer is characterized by the uncontrolled growth of cancerous cells in the breast tissue. It occurs in both males and females; however, male breast cancer is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer and other undifferentiated carcinoma. Ductal carcinoma is the form of breast cancer which starts in the lining of the milk ducts while lobular carcinoma begins in the milk glands of the breast. When breast cancer spreads from the site of origin to surrounding tissue, it is known as invasive breast cancer. Invasive ductal carcinoma is the most common subtype accounting for 70 to 80 percent of all the breast cases. In women, breast cancer is the second most common form of cancer. GLOBOCAN reported that in the year 2012, breast cancer accounted for 11.9 percent of the total cancer cases and lead to 5,22,000 deaths worldwide.
The analysts forecast the Global Breast Cancer market will grow at a CAGR of 11.61 percent over the period 2014-2018.
This report covers the present scenario and the growth prospects of the Global Breast Cancer market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sale of drugs used for the management of breast cancers including but not limited to:
- HER2-negative breast cancer
- HER2-positive breast cancer
- Hormone receptor positive breast cancer
- Hormone receptor negative breast cancer
- Advanced breast cancer
- Early breast cancer
- Operable node positive breast cancer
- Metastatic breast cancer
- Triple Negative Breast Cancer
The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Global Breast Cancer market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
The report, the Global Breast Cancer Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Breast Cancer market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Market Landscape
07. Treatment Regimen for Breast Cancer
08. Market Segmentation by Type of Therapy
09. Market Segmentation by Molecule Type
10. Global Monoclonal Antibodies Market in Breast Cancer
11. Clinical Pipeline Portfolio
12. Geographical Segmentation
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
21. Key Vendor Analysis
Companies Mentioned:
- Accord Healthcare
- Actavis
- Astrazeneca PLC
- Bayer AG
- BioMarin Pharmaceutical Inc.
- Bristol-Myers Squibb Company
- Celgene Corporation
- Celldex Therapeutics
- DARA BioSciences
- Eisai Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Galena Biopharma
- Gilead Sciences
- GlaxoSmithKline plc
- Hospira
- Immunovative Therapies
- Nektar Therapeutics
- Nippon Kayaku Co.
- Novartis AG
- Pfizer
- Pierre-Fabre Medicament
- ProStrakan
- Pt Dexa Medica
- Sanofi-Aventis
- Sorrento Therapeutics
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd
For more information visit http://www.researchandmarkets.com/research/8cfh9f/global_breast
Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net
